Search Results
Nov 13, 2025, 07:21 ET Sunlight.com Survey Finds GLP-1 Users Will Spend Twice as Much as Non-Users on Clothes This Black Friday
new report from Sunlight.com finds that Americans using GLP-1 medications are preparing for a major wardrobe refresh this Black Friday and Cyber Monday. The October 2025 survey of 1,500 U.S. adults reveals that GLP-1 users plan to spend more than twice as much on clothing as non-users,
More news about: Sunlight
Nov 12, 2025, 18:30 ET Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human
More news about: Ascletis Pharma Inc.
Nov 12, 2025, 18:30 ET 歌禮宣布每月一次新一代胰澱素受體激動劑ASC36和每月一次新一代GLP-1R/GIPR雙靶點激動劑ASC35的復方制劑進入臨床開發階段
View original content:https://www.prnewswire.com/apac/zh/news-releases/asc36glp-1rgiprasc35-302613290.html SOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Nov 12, 2025, 16:42 ET SHAKLEE SPARKLING PROTEIN™ RETURNS AFTER SELLING OUT IN RECORD TIME -- A RUNAWAY SUCCESS IN LONGEVITY NUTRITION
Shaklee Sparkling Protein delivers 40g of protein in a first-to-market sparkling beverage. Clinically tested to naturally boost GLP-1, it supports feelings of fullness, while its next-generation whey protein helps build and maintain muscle and supports metabolic wellness. Formulated
More news about: Shaklee
Nov 12, 2025, 11:15 ET APhA Foundation announces 2025 - 2026 Incentive Grant recipients
Pharmacist-led Patient Counseling to Increase GLP-1 Persistence Plus Diet Success and Satisfaction
More news about: American Pharmacists Association Foundation
Nov 12, 2025, 09:00 ET Lifeway Foods Delivers Record Q3 2025 Net Sales and Strong Net Income Growth Continuing Kefir Category Dominance
consistency of our growth trajectory. We will continue to capitalize on the powerful health and wellness consumer trends, including the surge in GLP-1 medication use and gut health awareness. We are investing heavily in our marketing efforts and our manufacturing capabilities to support our accelerating
More news about: Lifeway Foods, Inc.
Nov 12, 2025, 08:30 ET Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss
More news about: AbbVie
Nov 11, 2025, 17:24 ET CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
muscle preservation, and without GLP-1 target associated side effects—positions it as a potential new paradigm that could advance global obesity treatment beyond current GLP-1-based therapies. While GLP-1 receptor agonists like semaglutide have
More news about: CureGene
Nov 11, 2025, 08:49 ET Shed Expands Wellness and Weight-Management Services to Puerto Rico
in Puerto Rico include: Clinician-guided weight-management programs, including GLP-1 solutions One-on-one wellness and nutrition coaching Subscription plans and direct-to-door
More news about: Shed
Nov 11, 2025, 07:00 ET Little Rock Plastic Surgery Practice Introduces Medically-Supervised Weight Loss Program
sustainable weight loss under the care of experienced medical professionals. The program features FDA-approved GLP-1 medications, including semaglutide and tirzepatide, which have shown significant success in helping patients lose weight and improve overall metabolic
More news about: Dr. Suzanne Yee Cosmetic and Laser Surgery Center
Nov 10, 2025, 19:01 ET The Economist launches The World Ahead 2026-with rich countries living beyond their means, the risk of a bond-market crisis is growing
Ozempic, but better. Better, cheaper GLP-1 weight loss drugs are coming, and in pill form, too. That will expand access. But is taking them cheating, too? This year's
More news about: The Economist
Nov 10, 2025, 14:50 ET Kate Farms Expands Access with Launch of High Protein Nutrition Shakes at Select Walmart Stores: Clinically Designed Nutrition Support for GLP-1 Users and Everyday Wellness
nutrition during GLP-1 use when their appetite may be reduced. "High Protein Nutrition Shake was thoughtfully developed with health goals in mind," said Dr. Christina J. Valentine, MD, RDN, Chief Medical Officer at Kate Farms. "Making sure GLP-1 users are getting
More news about: Kate Farms, Inc
Nov 10, 2025, 13:28 ET As Access to Weight Loss Medication Expands, Foodsmart's 'GLP-1 Companion Care' Program Delivers Proven Medical and Pharmacy Savings through Integrated Nutrition and Lifestyle Management
provider nationwide, is expanding access to its GLP-1 Companion Care program after validating savings of $2,000 per GLP-1 patient annually versus those using medication alone. With the CMS announcement of expanding GLP-1 access for Medicaid and Medicare members who are
More news about: Foodsmart
Nov 10, 2025, 10:36 ET Gas Liquids Engineering conclui o Escopo de Emissão para Construção da instalação de exportação de energia de Ridley Island
localizada na Ilha Ridley, perto de Prince Rupert, na Colúmbia Britânica, e foi projetada para ser um terminal de exportação de gás liquefeito de petróleo (GLP) e líquidos a granel de acesso aberto, com uma capacidade de produção inicial estimada em 55.000 bbl/d de propano e butano. A instalação incorporará
More news about: GAS LIQUIDS ENGINEERING LTD.
Nov 10, 2025, 09:28 ET GLE finaliza la emisión del alcance de construcción de la planta de exportación de energía de Ridley Island
se ubica en la isla Ridley, cerca de Prince Rupert, Columbia Británica, y está diseñada como una terminal de exportación de gas licuado de petróleo (GLP) y líquidos a granel de acceso abierto, con una capacidad de procesamiento inicial estimada de 55.000 barriles diarios de propano y butano. La instalación
More news about: GAS LIQUIDS ENGINEERING LTD.
Nov 10, 2025, 09:12 ET Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Please see Indication and Safety Summary with
More news about: Eli Lilly and Company
Nov 10, 2025, 08:50 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
dysfunction-associated steatohepatitis (MASH) Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate-to-advanced liver scarring (fibrosis), but not with cirrhosis of
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
dysfunction-associated steatohepatitis (MASH) Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate-to-advanced liver scarring (fibrosis), but not with cirrhosis
More news about: NOVO NORDISK INC.
Nov 10, 2025, 02:44 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 is planned in an upcoming Phase 2b study." CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. Topline results from the Phase 1b study include:
More news about: Camurus AB
Nov 10, 2025, 02:41 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 is planned in an upcoming Phase 2b study." CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. Topline results from the Phase 1b study
More news about: Camurus AB
Nov 07, 2025, 16:07 ET Conheça os procedimentos que são eficazes para melhorar o rosto flácido após perda de peso induzida por medicamentos
7 de novembro de 2025 /PRNewswire/ -- A busca pelo emagrecimento a partir do uso de medicamentos específicos, como os análogos de GLP-1, tem se popularizado, trazendo consigo uma nova preocupação estética: as mudanças na pele e aparência do rosto, que podem surgir após a perda rápida
More news about: Galderma
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
augment endogenous GLP-1 action. GPR119 agonists directly stimulate GLP-1 secretion, thereby increasing total GLP-1 levels; when combined with a DPP4 inhibitor, the treatment can extend the action, not only of basal endogenous GLP-1, but also of the secreted
More news about: MetaVia Inc.
Nov 06, 2025, 22:30 ET Medicare Expands GLP-1 Coverage as MENU ORDER AI Prepares App Store Debut for the High-Protein / GLP-1 Dining Revolution
that Medicare will expand coverage for GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, MENU ORDER AI is preparing for its App Store debut—timed perfectly to serve the nation's growing population of GLP-1 users and health-conscious diners.
More news about: MENU - ORDER AI
Nov 06, 2025, 14:47 ET Nitinotes obtiene la marca CE para EndoZip™
de 650 millones de adultos en todo el mundo. Los tratamientos actuales presentan una importante brecha entre el manejo médico, como la terapia con GLP-1, y la cirugía bariátrica invasiva. La ESG se perfila como una alternativa mínimamente invasiva para pacientes con obesidad (IMC de 30 a 40 kg/m²) que
More news about: Nitinotes